Get access to the latest news and research in medical affairs with this comprehensive portal. Stay up-to-date with the latest clinical trials, studies, and developments in the medical field. Explore a variety of resources to enhance your knowledge and stay informed.
Solicite la visita de uno de nuestros delegados de GSK- Confirmación
Contacte con el centro de información, solicite la visita de un delegado o el contacto por el departamento médico, Notifique de una sospecha de reacción adversa
Severe asthma with eosinophilic phenotype is a distinct phenotype of severe asthma. This phenotype is characterized by airway inflammation, increased blood/sputum eosinophil (EOS) concentrations, poor asthma control, and increased rate of exacerbations.
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on measures of health status (SGRQ and CAT) according to different thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Poster PA1173
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on different lung function thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Presentation OA4653
Brooke M, et al. Patient advocacy advisors highlight disease stability as a desirable treatment goal for COPD, driven by patient aspirations and clinical characteristics. Personalisation of treatment strategies and patient care underpins the achievement and maintenance of disease stability resulting in improvements to the quality of life for patients living with COPD. Poster PA1171
Smith JA, et al. Prior and concomitant medication use in patients with refractory chronic cough: post-hoc analysis of SOOTHE. ERS 2024. Poster No. PA319
Video by Prof Dave Singh and Prof MeiLan Han describing disease stability and what it might mean for patients.
Short Video of RCC patient sharing the burden of this disease
Short video looking at the pathophysiology of refractory chronic cough
ERS 2024 supplemental symposium report
Can we break through the therapeutic ceiling in severe asthma? Prof. Celeste Porsbjerg - Professor of Severe Asthma - Bispebjerg Hospital, Denmark
Full symposium recording of Can we break through the therapeutic ceiling in severe asthma? Prof. Celeste Porsbjerg - Professor of Severe Asthma - Bispebjerg Hospital, Denmark
Poster PA1199 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Poster PA1198 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Poster PA1197 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Full recording of Striving for Disease Stability in COPD. Giving patients more if their best days. Co-Chairs by Meilan K. Han and Dave Singh Prof. MeiLan Han: Prof of Medicine, Divison of Pulmonary and Critical Care - University of Michigan, USA. Prof. Dave Singh: Prof of Respiratory Pharmacology, University of Manchester, UK. Dr. Lowie Vanfleteren: Head of the COPD Center - Sahgrenska University Hospital, Goffenburg, Sweden.
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
A collection of materials addressing Clinical Remission in asthma which is an ambitious but attainable treatment goal for patients with asthma irrespective of disease severity and treatment history
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents a sub-group analysis from the CAPTAIN study exploring the impact of type 2 biomarker status on outcomes.
Video recording of Prof. Oppenheimer providing an overview of clinical remission in asthma
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
GSK-GAA Webinar 2024: Optimising evidence through a patient-centred approach
GSK-GAA Webinar 2024: Panel Discussion
Short video summarising the IL-5 biology and recent evidence surrounding this science, as well as the cells impacted directly and indirectly by the IL-5 pathway.
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
GSK-GAA Webinar 2024: Personalized Asthma Care in the Clinic - Applying the latest evidence
For FF/UMEC/VI, the NMA suggest favourable efficacy compared with other single-inhaler triple therapies.
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
FF/UMEC/VI versus triple and dual bronchodilator therapies
Asthma is a heterogeneous disease and its management is multifactorial; many patients often remained uncontrolled despite treatment. HCPs have a critial role in identifying and managing patients who are not adequately controlled, which involves: -Regular discussions with patients -Recognition of symptoms and exacerbation risks -Continuous assessment of treatment -Reassessment of treatment and follow-up
How does molecule pharmacology correlate with clinical efficacy and safety? Pharmacological properties of inhaled respiratory molecules are critical to ensure the best possible clinical outcomes.
Comparing efficacy of triple therapies among patients with COPD. Multiple RCTs have demonstrated the benefit of triple over dual inhaled therapy in improving lung function and reducing the risk of exacerbation for patients with COPD
In this section the symptom burden and unmet needs of patients with COPD are discussed, as well as the importance of correct inhaler technique and the impact of multiple inhaler therapy.
What are the key considerations affecting inhaler choice, from a patient and physician perspective?
Clinical efficacy of inhaled therapy delivered via the Ellipta inhaler. As well as ease of use, and fewer patients making an error with their inhaler, treatments are needed that show clinical efficacy.
An interactive map displaying RWE studies in asthma, CRSwNP, EGPA, COPD and HES
Interactive pdf explaining the impact of IL-5 beyond eosinophils on cells. including its role in a variety of pathophysiological processes
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Short video with the faculty, summarising the key takeaways of the symposium.
Short Talking Head Videos outlining the unmet need in Refractory Chronic Cough and the importance of early recognition